STX Shield Therapeutics

Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous

Hardman & Co Research
Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous

12-Aug-2022 / 11:45 GMT/BST

Hardman & Co Video | Analyst interview

Shield Therapeutics (STX): Upside potential is enormous

Shield Therapeutics (STX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews.

Despite launching a drug into the US market, Shield has performed really badly over

the past 12 months, Martin explains what happened, shares his thoughts on the considerable progress made, implications for the full year, why the share price is falling, investment capital and the investment opportunity.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late stage, hospital focused pharmaceuticals.

 

Listen to the interview :

If you are interested in meeting the company, you can register your interest

Download our latest report on STX,

To contact us:

Hardman & Co
1 Frederick’s Place

London

EC2R 8AE

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall



+44 (0)203 693 7075

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1419419  12-Aug-2022 

fncls.ssp?fn=show_t_gif&application_id=1419419&application_name=news&site_id=research_pool
EN
12/08/2022

Underlying

STXShield Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shield Therapeutics

Hybridan Team
  • Hybridan Team
PEB Pebble Beach Sy...
SYS1 SYSTEM1 GROUP ... (+10)

Hybridan Small Cap Feast: 23/04/2025

Our daily digest of news from UK Small Caps 23rd April 2025 @HybridanLLP * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication, except Hybridan calculated the market capitalisation of Ethernity Networks ba...

PEB PEBBLE BEACH SYSTEMS GROUP
SYS1 SYSTEM1 GROUP
IOM IOMART GROUP PLC
AEO AEOREMA COMMUNICATIONS
STX SHIELD THERAPEUTICS
ENET ETHERNITY NETWORKS
TENG TEN LIFESTYLE GROUP
CSFS CORNERSTONE FS PLC
ATER ATERIAN INC
CODE NORTHCODERS GROUP PLC
04/23/25 April 23, 2025 1 EN
Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
IGP Intercede Group...
STX Shield Therapeu... ... (+11)

Hybridan Small Cap Feast: 12/03/2025

Our daily digest of news from UK Small Caps @HybridanLLP 12th March 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: Delistings: RA International Grou...

IGP INTERCEDE GROUP PLC
STX SHIELD THERAPEUTICS
TXG 10X GENOMICS INC CLASS A
AREC ARECOR THERAPEUTICS
ATER ATERIAN INC
COBR COBRA RESOURCES PLC
APTA APTAMER GROUP PLC
CPH2 CLEAN POWER HYDROGEN PLC
FMET FULCRUM METALS PLC
HEX HELIX EXPLORATION PLC
IES INVINITY ENERGY SYSTEMS PLC
03/12/25 March 12, 2025 1 EN
Free Trial
STX Shield Therapeu...

Shield Therapeutics: 1 director

A director at Shield Therapeutics bought 575,000 shares at 3.70p and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

STX SHIELD THERAPEUTICS
02/15/25 February 15, 2025 1 EN
Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
SCE Surface Transfo...
VLG Venture Life Gr... ... (+10)

Hybridan Small Cap Feast: 05/02/2025

* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: Today: RC Fornax (RCFX.L), the UK-based engineering consultancy for critical military platforms, announced its First Day of Dealings onto the AIM market. The...

SCE SURFACE TRANSFORMS PLC
VLG VENTURE LIFE GROUP
STX SHIELD THERAPEUTICS
DSG DILLISTONE GROUP
PRES PRESSURE TECHNOLOGIES
TND TANDEM GROUP PLC
B90 B90 HOLDINGS
APTD APTITUDE SOFTWARE GROUP
MTEC MADE TECH GROUP PLC
XSG XEROS TECHNOLOGY GROUP PLC
02/05/25 February 5, 2025 1 EN
Brian Moretta ... (+3)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
SN. SMITH & NEPHEW ...
AGL ANGLE PLC ... (+62)

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...

SN. SMITH & NEPHEW PLC
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
01/10/25 January 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch